[1]张胜月,刘红梅.活血化瘀中药调控肿瘤血管正常化研究进展[J].陕西中医,2026,(4):573-576，封3.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.028]
　ZHANG Shengyue,LIU Hongmei.Research progress on the regulation of tumor vascular normalization by blood-activating and stasis-resolving Chinese medicine[J].,2026,(4):573-576，封3.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.028]
点击复制

活血化瘀中药调控肿瘤血管正常化研究进展

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
573-576，封3
栏目:
综 述
出版日期:
2026-04-05

文章信息/Info

Title:
Research progress on the regulation of tumor vascular normalization by blood-activating and stasis-resolving Chinese medicine
作者:
张胜月1; 刘红梅2
（1.四川大学华西医院药剂科，四川 成都 610041；2.四川省医学科学院 四川省人民医院药学部，四川 成都 610072）
Author(s):
ZHANG Shengyue1; LIU Hongmei2
(1.Department of Pharmacy,West China Hospital of Sichuan University,Chengdu 610041,China;2.Department of Pharmacy,Sichuan Academy of Medical Sciences，Sichuan Provincial People’s hospital,Chengdu 610072,China)
关键词:
恶性肿瘤; 血管正常化; 活血化瘀; 中药单体; 中药复方
Keywords:
Malignant tumors; Vascular normalization; Blood-activating and stasis-resolving; Single herb component; Herbal compound
分类号:
R 73
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.028
文献标志码:
A
摘要:
实体瘤中，血管的结构与功能高度异常形成免疫抑制肿瘤微环境，加剧恶性肿瘤进展、侵袭与耐药；近年来，诱导血管正常化作为抗肿瘤策略的新方向受到广泛关注。活血化瘀法是中医药对肿瘤的基本治则之一，在调控肿瘤血管正常化方面具有独特优势。基于肿瘤血管异常发生机制与中医药理论，系统梳理活血化瘀中药及复方在诱导肿瘤血管正常化的研究进展，探讨其多靶点、多通路协同调控机制，旨在为活血化瘀中药通过调控肿瘤血管正常化发挥抗肿瘤作用提供理论支撑和研究思路。
Abstract:
In solid tumors,structural and functional abnormalities of blood vessels contribute to the formation of an immunosuppressive tumor microenvironment,thereby accelerating malignant tumor progression,invasion,and therapeutic resistance.In recent years,the induction of vascular normalization has emerged as a promising therapeutic strategy in oncology.As one of the fundamental principles of traditional Chinese medicine (TCM),blood-activating and stasis-resolving Chinese medicine has shown unique advantages in regulating tumor vascular normalization.Based on the pathophysiology of tumor vascular abnormalities and TCM theory,this review systematically summarizes recent advances in the application of blood-activating and stasis-resolving Chinese medicine and classical herbal formulas in inducing tumor vascular normalization.Furthermore,the multi-target,multi-pathway synergistic regulatory mechanisms are discussed,aiming to provide a theoretical foundation and research perspective for the use of these therapies in tumor microenvironment modulation and anti-tumor treatment.

参考文献/References:

[1]MPEKRIS F,PANAGI M,CHARALAMBOUS A,et al.Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy[J].Cell Rep Med,2024,5(7):101626.
[2]杨文笑,王程燕,焦丽静,等.从肿瘤血管正常化探讨益气养阴法防治肺癌转移的机制[J].河北中医,2024,46(8):1366-1369.
[3]伏杰,王松坡,李琦,等.活血化瘀中药抗肿瘤血管新生的实验研究进展[J].中华中医药学刊,2020,38(4):153-157.
[4]WU S,SUN Z,GUO Z,et al.The effectiveness of blood-activating and stasis-transforming traditional Chinese medicines (BAST) in lung cancer progression-a comprehensive review[J].J Ethnopharmacol,2023,314:116565.
[5]JAIN R K.Normalization of tumor vasculature:An emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62.
[6]唐振豪,兰聪颖,林丽珠.从肿瘤微环境正常化探讨活血化瘀法及除痰散结法在肿瘤治疗中的机制[J].广州中医药大学学报,2019,36(7):1091-1098.
[7]郭嘉宁,倪晓晨,张开源,等.丹参及其活性成分抗结直肠癌的分子机制研究进展[J].中国实验方剂学杂志,2026,32(4):307-314.
[8]SHATAT A S,MAHGOUP E M,RASHED M H,et al.Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression:Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR[J].Purinergic Signal,2024,20(6):669-680.
[9]QIAN C,YANG C,TANG Y,et al.Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy[J].Pharmacol Res,2022,182:106333.
[10]JIN L,CHEN C,HUANG L,et al.Salvianolic acid A blocks vasculogenic mimicry formation in human non-small cell lung cancer via PI3K/Akt/mTOR signalling[J].Clin Exp Pharmacol Physiol,2021,48(4):508-514.
[11]安庆文.基于活血化瘀法探讨丹参二萜醌通过JAK1/STAT3通路治疗血瘀证肺癌[D].杭州：浙江中医药大学,2023.
[12]TANG D,ZHANG S,SHI X,et al.Combination of astragali polysaccharide and curcumin improves the morphological structure of tumor vessels and induces tumor vascular normalization to inhibit the growth of hepatocellular carcinoma[J].Integr Cancer Ther,2019,18:1534735418824408.
[13]WENG W,GOEL A.Curcumin and colorectal cancer:An update and current perspective on this natural medicine[J].Semin Cancer Biol,2022,80:73-86.
[14]VILLEGAS C,PEREZ R,STERNER O,et al.Curcuma as an adjuvant in colorectal cancer treatment[J].Life Sciences,2021,286:120043.
[15]史新萌,刘玉萍,瞿鼎,等.抑制HIF-1α表达的中药抗肿瘤活性成分研究进展[J].药学学报,2021,56(10):2689-2719.
[16]岳盼.红花水提物通过下调脂肪酸β-氧化通路抑制斑马鱼胚胎血管生成的研究[D].成都：成都中医药大学,2021.
[17]郑烨韵,周凤华.红花黄色素抗肿瘤机制新进展[J].中药药理与临床,2023,39(7):126-129.
[18]ZHANG J,LI J,SONG H,et al.Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation[J].Biomed Pharmacother,2019,109:806-814.
[19]LIN J,WANG Q,ZHOU S,et al.Tetramethylpyrazine:A review on its mechanisms and functions[J].Biomed Pharmacother,2022,150:113005.
[20]张健萍,裴容,汪海燕,等.川芎嗪单独及联合西药抗肿瘤作用研究进展[J].中国实验方剂学杂志,2022,28(14):235-241.
[21]路旭辉,周玲,郝玉梅.川芎挥发油调控PI3K/Akt信号通路对胶质瘤细胞替莫唑胺耐药性的影响研究[J].中国临床神经科学,2025,33(1):10-18.
[22]ZOU L,LIU X,LI J,et al.Tetramethylpyrazine enhances the antitumor effect of paclitaxel by inhibiting angiogenesis and inducing apoptosis[J].Front Pharmacol,2019,10:707.
[23]杨忠英,岳德永,程凤姣.复方斑蝥胶囊对肝癌细胞Hippo/YAP通路及血管生成拟态的影响[J].中国药师,2021,24(11):1983-1986，1992.
[24]ZHANG J T,SUN W,ZHANG W Z,et al.Norcantharidin inhibits tumor growth and vasculogenic mimicryof human gallbladder carcinomas by suppression of the PI3K/MMPs/Ln-5γ2 signaling pathway[J].BMC Cancer,2014,14:193.
[25]刘丝雨,田赛男,李东芳,等.去甲斑蝥素在乳腺癌中的研究进展[J].肿瘤药学,2023,13(2):155-160.
[26]ZHOU J B,REN Y L,TAN L,et al.Norcantharidin:Research advances in pharmaceutical activities and derivatives in recent years[J].Biomedicine & Pharmacotherapy,2020,131:110755.
[27]李园媛.水蛭提取液对视网膜母细胞瘤的抑制作用及相关分子机制研究[D].成都：成都中医药大学,2020.
[28]谢兴文,王小强,徐世红,等.基于破血逐瘀理论探讨中药水蛭及其复方治疗肿瘤的研究进展[J].中华中医药学刊,2024,42(3):1-4.
[29]ZHAO J J,LI Z H,ZHANG H X,et al.Recombinant hirudin suppresses angiogenesis of diffuse large B-cell lymphoma through regulation of the PAR-1-VEGF[J].Chemical Biology & Drug Design,2024,103(5):e14533.
[30]ZHAO B,WU M F,HU Z H,et al.A novel oncotherapy strategy:Direct thrombin inhibitors suppress progression,dissemination and spontaneous metastasis in non-small cell lung cancer[J].Br J Pharmacol,2022,179(22):5056-5073.
[31]么杨,赵良.桃红四物汤治疗晚期非小细胞肺癌血瘀证临床观察[J].中国中医药现代远程教育,2021,19(6):90-92.
[32]CHENG Y,LI J,FENG X,et al.Taohong Siwu decoction enhances the chemotherapeutic efficacy of doxorubicin by promoting tumor vascular normalization[J].Phytomedicine,2024,134:155995.
[33]赵悦欣,陈乐君,刘婕,等.血府逐瘀汤对人食管癌ECA-109荷瘤裸鼠肿瘤血管的影响[J].中医药信息,2024,41(4):35-39.
[34]孟田田,张桐桐,邓秋,等.血府逐瘀汤辅助XELOX化疗治疗对晚期肝癌患者血清HIF-1α及TSP-1表达的影响[J].中西医结合肝病杂志,2022,32(7):606-609.
[35]张岚,宋磊,李德需,等.生脉饮合血府逐瘀汤对非小细胞肺癌血液高凝状态的影响[J].中国实验方剂学杂志,2019,25(11):109-114.
[36]李杳瑶,刘华,孙铜林,等.鳖甲煎丸经AT1R/VEGF信号通路对肝癌血管生成的影响[J].解剖学研究,2023,45(6):523-528.
[37]安海燕,林俊豪,孙海涛,等.鳖甲煎丸通过RhoA/ROCK信号通路抑制肝癌细胞血管形成拟态的生成[J].南方医科大学学报,2018,38(8):997-1001.
[38]李杳瑶,刘华,孙铜林,等.鳖甲煎丸联合阿帕替尼对中晚期肝癌TACE术后患者Th17/Treg平衡、凋亡分子和血管生成因子的影响[J].现代生物医学进展,2024,24(7):1291-1295.
[39]DING W,CHEN X,YANG L,et al.Combination of Shuangdan capsule and Sorafenib inhibits tumor growth and angiogenesis in hepatocellular carcinoma via PI3K/Akt/mTORC1 pathway[J].Integr Cancer Ther,2022,21:15347354221078888.

相似文献/References:

[1]万晓燕.芪术茯苓汤治疗恶性肿瘤化疗后白细胞减少临床研究[J].陕西中医,2019,(1):100.
　WAN Xiaoyan..Clinical study of Qizhu Fuling decoction in the treatment of malignant tumor after chemotherapy of white blood cell reduction[J].,2019,(4):100.
[2]任 伟,王巧云.参丹散结胶囊联合核磁共振引导下的高强度聚焦超声消融 治疗妇科恶性肿瘤骨转移临床研究*[J].陕西中医,2019,(5):648.
　REN Wei,WANG Qiaoyun..Effect of Danshen Sanjie capsule combined with magnetic resonance imaging guided high intensity focused ultrasound ablation in the treatment of gynecologic malignant tumor bone metastasis[J].,2019,(4):648.
[3]刘包欣子,金志超,邵 杰,等.王瑞平教授运用解毒散结对药治疗恶性肿瘤经验[J].陕西中医,2021,(11):1601.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.025]
　LIU Baoxinzi,JIN Zhichao,SHAO Jie,et al.Professor WANG Ruiping's experience in treating malignant tumors with paired detoxification and Sanjie herbs[J].,2021,(4):1601.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.025]
[4]简小兰,蒋益兰,蒋盛昶.蒋益兰教授治疗恶性肿瘤骨转移经验[J].陕西中医,2022,(5):620.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.018]
　JIAN Xiaolan,JIANG Yilan,JIANG Shengchang.Experiences from Professor JIANG Yilan in treating bone metastasis of malignant tumour[J].,2022,(4):620.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.018]
[5]陈 玉,肖海娟,王惠玲,等.基于伏邪理论探讨恶性肿瘤发病机制[J].陕西中医,2022,(12):1760.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.026]
[6]梁奡晟雄,周红光.温滋解毒法治疗恶性肿瘤理论探讨[J].陕西中医,2023,(7):913.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.020]
[7]丁艳琦,郝皖蓉,冷玉玲,等.草灵丹加减联合温经浴袋改善恶性肿瘤患者高凝状态临床观察[J].陕西中医,2024,(5):646.[doi:DOI:10.3969/j.issn.1000-7369.2024.05.016]
　DING Yanqi,HAO Wanrong,LENG Yuling,et al.Clinical efficacy of modified Caoling pill combined with warming meridian bath bag on improving hypercoagulable state in patients with malignant tumors[J].,2024,(4):646.[doi:DOI:10.3969/j.issn.1000-7369.2024.05.016]
[8]殷华芳,奚 蕾,沈卫东,等.名中医沈伟生基于“治未病”理念防治恶性肿瘤经验[J].陕西中医,2024,(10):1411.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.026]
　YIN Huafang,XI Lei,SHEN Weidong,et al.Shen Weisheng's experience in preventing and treating malignant tumors based on concept of “Preventive treatment of disease” theory[J].,2024,(4):1411.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.026]
[9]屈建敏,王 刚.手足综合征中医研究进展[J].陕西中医,2024,(10):1438.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.033]
　QU Jianmin,WANG Gang.Progress of Chinese medicine research on hand-foot syndrome[J].,2024,(4):1438.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.033]
[10]张兴涵,刘梓燊,苏怡,等.名中医杨国旺基于去兼除夹法运用炙甘草汤治疗恶性肿瘤经验[J].陕西中医,2026,(4):526.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.018]
　ZHANG Xinghan,LIU Zishen,SU Yi,et al.Experience of famous traditional Chinese medicine doctor YANG Guowang in treating malignant tumors with Zhigancao decoction based on the method of removing concurrent and accompanying pathogens[J].,2026,(4):526.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.018]

备注/Memo

备注/Memo:
国家自然科学基金青年基金资助项目（82304969）；中国博士后科学基金会资助面上项目（2022M710623）；济仁慈善基金会资助项目（济基发字〔2025〕第HT-XM-20251119-1153号）
更新日期/Last Update: 2026-04-05